What do BEL512 Phase 2 results mean for Belenos Biosciences and CRSwNP treatment?
Belenos says BEL512 met all Phase 2 CRSwNP endpoints, but undisclosed effect sizes make the planned 2027 Phase 3 trial the critical test.
Pharma & Biotech
Pharma & Biotech
GSK’s Exdensur wins FDA nod for severe asthma: Can twice-yearly dosing reset the biologics playbook?
GSK’s Exdensur has been approved by the FDA as the first biannual biologic for severe asthma. Find out what this means for patients, payers, and rivals.